| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Robbie Marcus maintains RxSight (NASDAQ:RXST) with a Underweight and raises the price target from $8 to $9.
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and raises the price target from $9 ...
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and raises the price target from $11 to $12.
RxSight (NASDAQ:RXST) raises FY2025 sales outlook from $120.000 million-$130.000 million to $125.000 million-$130.000 million v...
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.38) by 89...
UBS analyst Danielle Antalffy maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $16 to $8.
Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $9 to $8.